![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Samaneh Kalirai, Jasmina I Ivanova, Magaly Perez-Nieves, Judith J Stephenson, Irene Hadjiyianni, Michael Grabner, Roy Daniel Pollom, Caroline Geremakis, Beverly L Reed & Lawrence Fisher. (2020) Basal Insulin Initiation and Maintenance in Adults with Type 2 Diabetes Mellitus in the United States. Diabetes, Metabolic Syndrome and Obesity 13, pages 1023-1033.
Read now
Read now
Arto Y. Strandberg, Houssem Khanfir, Sari Mäkimattila, Tero Saukkonen, Timo E. Strandberg & Fabian Hoti. (2017) Insulins NPH, glargine, and detemir, and risk of severe hypoglycemia among working-age adults*. Annals of Medicine 49:4, pages 357-364.
Read now
Read now
Mehul R. Dalal, Mahmood R. Kazemi & Fen Ye. (2017) Hypoglycemia in patients with type 2 diabetes newly initiated on basal insulin in the US in a community setting: impact on treatment discontinuation and hospitalization. Current Medical Research and Opinion 33:2, pages 209-214.
Read now
Read now
Magaly Perez-Nieves, Samaneh Kabul, Urvi Desai, Jasmina I. Ivanova, Noam Y. Kirson, Alice Kate Cummings, Howard G. Birnbaum, Ran Duan, Dachuang Cao & Irene Hadjiyianni. (2016) Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US. Current Medical Research and Opinion 32:4, pages 669-680.
Read now
Read now
Karel Kostev, Franz W Dippel & Wolfgang Rathmann. (2015) Glycemic control after initiating basal insulin therapy in patients with type 2 diabetes: a primary care database analysis. Diabetes, Metabolic Syndrome and Obesity 8, pages 45-48.
Read now
Read now
Andres Digenio, Sudeep Karve, Sean D. Candrilli & Mehul Dalal. (2014) Prandial Insulin versus Glucagon-Like Peptide-1 Added to Basal Insulin: Comparative Effectiveness in the Community Practice Setting. Postgraduate Medicine 126:6, pages 49-59.
Read now
Read now
Articles from other publishers (22)
Thomas Forst, Pratik Choudhary, Doron Schneider, Bruno Linetzky & Paolo Pozzilli. (2020) A practical approach to the clinical challenges in initiation of basal insulin therapy in people with type 2 diabetes. Diabetes/Metabolism Research and Reviews 37:6.
Crossref
Crossref
I. N. Dyakov & S. K. Zyryanov. (2020) Pharmacoeconomic comparison of insulin glargine and insulin detemir in diabetes mellitus type 2. Kachestvennaya klinicheskaya praktika:3, pages 4-14.
Crossref
Crossref
G. González-Gálvez, M.L. Díaz-Toscano, J.F. Llamas-Moreno, K. Fernández-Rodarte & M.E. Sañudo-Maury. (2020) Mexican population sub-analysis of the lixilan clinical program with the fixed ratio combination of insulin glargine and lixisenatide (iGlarLixi). Journal of Diabetes and its Complications 34:8, pages 107389.
Crossref
Crossref
Olga Montvida, John Epoh Dibato & Sanjoy Paul. (2020) Evaluating the Representativeness of US Centricity Electronic Medical Records With Reports From the Centers for Disease Control and Prevention: Comparative Study on Office Visits and Cardiometabolic Conditions. JMIR Medical Informatics 8:6, pages e17174.
Crossref
Crossref
Lawrence Blonde, Stephen A. Brunton, Pavan Chava, Rong Zhou, Juliana Meyers, Keith L. Davis, Mehul R. Dalal & Andres DiGenio. (2019) Achievement of Target A1C <7.0% (<53 mmol/mol) by U.S. Type 2 Diabetes Patients Treated With Basal Insulin in Both Randomized Controlled Trials and Clinical Practice. Diabetes Spectrum 32:2, pages 93-103.
Crossref
Crossref
Rebecca S. Holmes, Elizabeth Crabtree & Marian S. McDonagh. (2019) Comparative effectiveness and harms of long‐acting insulins for type 1 and type 2 diabetes: A systematic review and meta‐analysis. Diabetes, Obesity and Metabolism 21:4, pages 984-992.
Crossref
Crossref
Fang Liz Zhou, Jason Yeaw, Swapna U Karkare, Mitch DeKoven, Paulos Berhanu & Timothy Reid. (2018) Impact of a structured patient support program on adherence and persistence in basal insulin therapy for type 2 diabetes. BMJ Open Diabetes Research & Care 6:1, pages e000593.
Crossref
Crossref
Mehul R. Dalal, Mahmood Kazemi, Fen Ye & Lin Xie. (2017) Hypoglycemia After Initiation of Basal Insulin in Patients with Type 2 Diabetes in the United States: Implications for Treatment Discontinuation and Healthcare Costs and Utilization. Advances in Therapy 34:9, pages 2083-2092.
Crossref
Crossref
Olga Montvida, Ognjen Arandjelović, Edward Reiner & Sanjoy K. Paul. (2017) Data Mining Approach to Estimate the Duration of Drug Therapy from Longitudinal Electronic Medical Records. The Open Bioinformatics Journal 10:1, pages 1-15.
Crossref
Crossref
Wenhui Wei, Jenny Jiang, Youbei Lou, Sohini Ganguli & Mark S. Matusik. (2017) Benchmarking Insulin Treatment Persistence Among Patients with Type 2 Diabetes Across Different U.S. Payer Segments. Journal of Managed Care & Specialty Pharmacy 23:3, pages 278-290.
Crossref
Crossref
Olga Montvida, Kerenaftali Klein, Sudhesh Kumar, Kamlesh Khunti & Sanjoy K. Paul. (2017) Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients. Diabetes, Obesity and Metabolism 19:1, pages 108-117.
Crossref
Crossref
S. K. Paul, J. E. Shaw, O. Montvida & K. Klein. (2016) Weight gain in insulin-treated patients by body mass index category at treatment initiation: new evidence from real-world data in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 18:12, pages 1244-1252.
Crossref
Crossref
Samuel StolpeMichel A. KroesNeil WebbTami Wisniewski. (2016) A Systematic Review of Insulin Adherence Measures in Patients with Diabetes. Journal of Managed Care & Specialty Pharmacy 22:11, pages 1224-1246.
Crossref
Crossref
Ming‐Nan Chien, Yen‐Ling Chen, Yi‐Jen Hung, Shu‐Yi Wang, Wen‐Tsung Lu, Chih‐Hung Chen, Ching‐Ling Lin, Tze‐Pao Huang, Ming‐Han Tsai, Wei‐Kung Tseng, Ta‐Jen Wu, Cheng Ho, Wen‐Yu Lin, Bill Chen & Lee‐Ming Chuang. (2016) Glycemic control and adherence to basal insulin therapy in Taiwanese patients with type 2 diabetes mellitus. Journal of Diabetes Investigation 7:6, pages 881-888.
Crossref
Crossref
Jamie T. TaSara C. EricksonWenyi (Amanda) QiuBimal V. Patel. (2016) Is There a Relationship Between Part D Medication Adherence and Part C Intermediate Outcomes Star Ratings Measures?. Journal of Managed Care & Specialty Pharmacy 22:7, pages 787-795.
Crossref
Crossref
Philip Levin, Steve Zhou, Emily Durden, Amanda M. Farr, Jasvinder Gill & Wenhui Wei. (2016) Clinical and Economic Outcomes Associated With the Timing of Initiation of Basal Insulin in Patients With Type 2 Diabetes Mellitus Previously Treated With Oral Antidiabetes Drugs. Clinical Therapeutics 38:1, pages 110-121.
Crossref
Crossref
Stefan Pscherer, Engels Chou, Franz-Werner Dippel, Wolfgang Rathmann & Karel Kostev. (2015) Treatment persistence after initiating basal insulin in type 2 diabetes patients: A primary care database analysis. Primary Care Diabetes 9:5, pages 377-384.
Crossref
Crossref
Gregory Fulcher, Anthony Roberts, Ashim Sinha & Joseph Proietto. (2015) What happens when patients require intensification from basal insulin? A retrospective audit of clinical practice for the treatment of type 2 diabetes from four Australian centres. Diabetes Research and Clinical Practice 108:3, pages 405-413.
Crossref
Crossref
P. Levin, W. Wei, R. Miao, F. Ye, L. Xie, O. Baser & J. Gill. (2014)
Therapeutically interchangeable? A study of real‐world outcomes associated with switching basal insulin analogues among
US
patients with type 2 diabetes mellitus using electronic medical records data
. Diabetes, Obesity and Metabolism 17:3, pages 245-253.
Crossref
Crossref
Wenhui Wei, Steve Zhou, Raymond Miao, Chunshen Pan, Lin Xie, Onur Baser & Jasvinder Gill. (2014) Much Ado About Nothing? A Real-World Study of Patients with Type 2 Diabetes Switching Basal Insulin Analogs. Advances in Therapy 31:5, pages 539-560.
Crossref
Crossref
Wenhui Wei, Chunshen Pan, Lin Xie & Onur Baser. (2014) Real-World Insulin Treatment Persistence among Patients with Type 2 Diabetes. Endocrine Practice 20:1, pages 52-61.
Crossref
Crossref
YOUNG RAE KIM, JONG SEOK LEE, KI RIM LEE, YOUNG EON KIM, NAM IN BAEK & EOCK KEE HONG. (2014) Effects of mulberry ethanol extracts on hydrogen peroxide-induced oxidative stress in pancreatic β-cells. International Journal of Molecular Medicine 33:1, pages 128-134.
Crossref
Crossref